Y-mAbs Therapeutics A/S
CVR 37053678 · Public limited company (A/S) · Active · Low risk
Y-mAbs Therapeutics A/S is a Public limited company (A/S), founded on , based in Hørsholm. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 0.9% over the next 12 months, which is 0.6 times the average for Danish companies. 10 annual reports have been published, of which 2 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK -163.7m and a net result of DKK -38.5m.
Bankruptcy risk for Y-mAbs Therapeutics A/S
0.6 × the average (1.41%) · higher risk than 69% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 37053678
- Status
- Active
- Company type
- Public limited company (A/S)
- Founded
- (11 years)
- Address
- Agern Alle 13
2970 Hørsholm - Municipality
- Rudersdal
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 9.8m
- Employees
- 24 (2018)
- Auditor
- EY Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 2 of 10 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -1,087.9% |
| Current ratio | 7% |
| Moves (last 2 years) | 1 |
| CEO changes in total | 1 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 0 |
| Going-concern uncertainty | Yes |
Financials and key figures
| Financial year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Gross profit | DKK 29.3m | DKK 74.3m | DKK 70.7m |
| Net profit | DKK -38.5m | DKK -12.5m | DKK -27.7m |
| Equity | DKK -163.7m | DKK -125.2m | DKK -112.7m |
| Total assets | DKK 15.0m | DKK 26.5m | DKK 56.7m |
| Cash | DKK 4.2m | DKK 5.3m | – |
| Short-term debt | DKK 172.6m | DKK 145.8m | – |
| Avg. employees | 53 | 56 | – |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · EY Godkendt Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 176 | ||
| 1 Jan 2024 – 31 Dec 2024 | 189 | Late | |
| 1 Jan 2023 – 31 Dec 2023 | 181 | ||
| 1 Jan 2022 – 31 Dec 2022 | 191 | Late | |
| 1 Jan 2021 – 31 Dec 2021 | 181 | ||
| 1 Jan 2020 – 31 Dec 2020 | 155 | ||
| 1 Jan 2019 – 31 Dec 2019 | 148 | ||
| 1 Jan 2018 – 31 Dec 2018 | 149 | ||
| 1 Jan 2017 – 31 Dec 2017 | 151 | ||
| 27 Aug 2015 – 31 Dec 2016 | 158 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Claus Juan Møller-San Pedro | ||
| Board | Antoine Bernasconi | Current | |
| Board | Vincent Sainte-Catherine | Current | |
| Board | Julien Forest | Current | |
| Board | Claus Juan Møller-San Pedro | ||
| Board | Thomas Gad | ||
| Board | Bo Kruse | ||
| Board | Johan Ernst Wedell-Wedellsborg | ||
| Board | Gregory Stephen Raskin | ||
| Board | Ashutosh Tyagi | ||
| Board | David Neil Gill | ||
| Board | Michael Joachim Buschle | ||
| Board | Jim Irvin Healy | ||
| Board | Gérard Ber | ||
| Board | Laura J. Hamill | ||
| Board | Bo Kruse | ||
| Board | Johan Ernst Wedell-Wedellsborg | ||
| Board | Thomas Gad | ||
| Board | Bo Kruse | ||
| Board | Michael Joseph Rossi | ||
| Board | Thomas Gad | ||
| Board | Peter Paul Pfreundschuh | ||
| Owner (100%) | Y-mAbs Therapeutics, Inc. | Current | |
| Auditor | EY Godkendt Revisionspartnerselskab | Current | |
| Auditor | PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB | ||
| Founder | Y-MABS THERAPEUTICS, INC. | Current |
The CEOs' other companies
Claus Juan Møller-San Pedro – 36 other companies, of which 11 bankrupt
- AKSELTORV 5-13 ApS Bankrupt 9 Nov 2012
- CM SHIPPING ApS Bankrupt 9 Nov 2012
- EINSTEINIUM ApS Bankrupt 7 Jan 2011
- EJENDOMSSELSKABET GLASSICET ApS Bankrupt 9 Nov 2012
- FELDING MOSE III ApS Bankrupt 9 Nov 2012
- FREDERICIAGADE 7-13 ApS Bankrupt 28 Jun 2010
- HAUSER PLADS 28-32 ApS Bankrupt 28 Jun 2010
- I. P. CONS ApS Bankrupt 7 Jul 2015
- STANFORD ApS Bankrupt 19 Mar 2012
- SYDPORTEN ApS Bankrupt 14 Jun 2010
- TOLDBODGADE 29 ApS Bankrupt 28 Jun 2010
- ASTRA BILLEDDIAGNOSTIK A/S Fusioneret
- AZANTA A/S Active
- AZANTA DANMARK A/S Active
- Afyx Capital ApS Active
- Afyx Development A/S Active
- Afyx Therapeutics A/S Active
- BARKA Therapeutics ApS Active
- BEKKEVOLD KLINIKKEN A/S Fusioneret
- CENTER FOR BILLEDDIAGNOSTIK ApS Fusioneret
- Capio A/S Active
- EPITHERAPEUTICS ApS Opløst
- GENMAB A/S Active
- GLASSICET 2 ApS Opløst
- IPC PHARMA A/S Opløst
- IPC RESEARCH & DEVELOPMENT ApS Fusioneret
- Kiva Stones ApS Opløst
- KØBENHAVNS PRIVATHOSPITAL A/S Fusioneret
- NEOLOCH ApS Opløst
- NYGADE 5. 1995 ApS Opløst
Address history (2 moves)
| Agern Alle 13, 2970 Hørsholm | |
| Agern Alle 11, 2970 Hørsholm | |
| Rungsted Strandvej 113, 2960 Rungsted Kyst |
Employees per year
Similar companies in Rudersdal
- GigaVax ApS Holte
- Migalis ApS Vedbæk
- LIVAG ApS Vedbæk
- CysBio ApS Hørsholm
- Ceremedy ApS Virum
- Cell to Cure ApS Birkerød
- JKastrup.ApS Birkerød
- immunAware ApS Hørsholm
- ASTIM Holding ApS Birkerød
- ASRØ Holding ApS Nærum
- Detalo Instruments Aps Birkerød
- ResoTher Pharma A/S Holte
Questions and answers about Y-mAbs Therapeutics A/S
Has Y-mAbs Therapeutics A/S gone bankrupt?
No, Y-mAbs Therapeutics A/S is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Y-mAbs Therapeutics A/S?
Our model estimates a bankruptcy risk of 0.9% over the next 12 months (low risk), which is 0.6 times the average for Danish companies.
Who is the auditor of Y-mAbs Therapeutics A/S?
Y-mAbs Therapeutics A/S most recently used EY Godkendt Revisionspartnerselskab.
When was Y-mAbs Therapeutics A/S founded?
Y-mAbs Therapeutics A/S was founded on 27 August 2015.
What is the equity of Y-mAbs Therapeutics A/S?
Equity was DKK -163.7m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.